

SITE DIRECTED MUTAGENESIS OF TWO CYSTEINE RESIDUES IN THE *E. COLI* OGT O⁶-ALKYLGUANINE DNA ALKYLTRANSFERASE PROTEIN

L. C. Harris^{1,2}, P. M. Potter¹, and G. P. Margison

CRC Department of Chemical Carcinogenesis, Paterson Institute for Cancer Research, Christie Hospital and Holt Radium Institute, Manchester, M20 9BX, UK

Received July 7, 1992

The *E. coli* *ogt* O⁶-alkylguanine-DNA alkyltransferase has two cysteine residues positioned identically with respect to cysteines in the *E. coli* *ada* O⁶-alkylguanine-DNA alkyltransferase. In order to assess their function, these residues were each substituted by a glycine to generate altered forms of the *ogt* protein. Mutagenesis of cysteine-139, located within a 'PCHRV' region of homology, eliminated functional activity confirming that this residue is the methyl-accepting cysteine in the active site of the protein. Substitution of cysteine 102 within the sequence 'LRTIPCG' had little effect on the *ogt* protein activity demonstrating that this cysteine is not directly involved with the transfer of O⁶-methylguanine adducts.

© 1992 Academic Press, Inc.

Monofunctional alkylating agents produce the toxic and mutagenic lesions, O⁶-alkylguanine and O⁴-alkylthymine in DNA (1). O⁶-alkylguanine-DNA alkyltransferase (ATase) is a ubiquitous protein which can specifically repair these adducts by the direct transfer of the alkyl group to a cysteine residue within ATases (2). *E. coli* has two genes, *ada* (3,4) and *ogt* (5) which each encode an ATase enzyme. The *ogt* gene constitutively expresses a 19 kDa protein which constitutes the majority of the ATase measurable in wild type *E. coli* (6) whereas the *ada* gene is inducible by sub-lethal doses of alkylating agents (7) and encodes a 39 kDa ATase protein. This protein is cleaved *in vivo* into a 20 kDa peptide which is capable of repairing S-stereo-isomers of methylphosphotriesters and an 18 kDa peptide which is responsible for the repair of O⁶-alkylguanine and O⁴-alkylthymine adducts in DNA (4). The *ogt* ATase amino acid sequence is 28% homologous to the 18 kDa subfragment of the *ada* protein and 49% homologous to the 94 carboxyterminal amino acids

¹Present address: Department of Pharmacology, St. Jude Children's Research Hospital, Memphis, TN 38101.

²To whom correspondence should be addressed.

Abbreviations

ATase, O⁶-alkylguanine-DNA alkyltransferase (E.C.2.1.1.63); IPTG, Isopropylthio- β -Galactoside; MNU, N-methyl-N-nitrosourea.

		Cleavage site
ada	179	QFRHGGENLAVRYALADCELGRCLVAESERGICAILLGDDD
ogt	1 MLRLLEEKIATPLGPLWVICDEQFRLRAVEWEEYSER
ada	220	ATLISELQQMFPAADNAPADLMFQQHVREVIASLNQRDTPL
ogt	38	MVQLLDIHYRKEGYERISATNPGGLSDKLRDYFAGNLSIID
ada	261	TLPLDIRGTAFQQQVWQALRTIPCGETVSYQQLANAIGKPK
ogt	79	TLPTATGGTTPFQREVKTLRTIPCGQVMHYGQLAEQLGRPG
		*
ada	302	AVRAVASACAAANKLAIVIPCHRVVRGDGSLSGYRWGVSRKA
ogt	120	AARAVGAAANGSNPISIVVPCHRVIGRNGTMTGYAGGVQRKE
		*
ada	343	QLLRREAEENEER
ogt	161	WLLRHEGYLLL

Figure 1

A comparison of the amino acid sequences of the *ogt* ATase and the 18 kDa subfragment of the *ada* ATase. The regions of homology are boxed and the cysteine residues which were substituted are marked (*).

(Fig. 1). In particular, there are two regions of homology which contain cysteine residues; a heptameric (LRTIPCG), and a pentameric (PCHRV) sequence separated by 38 amino acids in each protein (Fig. 1). Cysteine residue 321 in the *ada* protein has been identified as the alkyl-acceptor cysteine (8) and therefore the corresponding residue in the *ogt* protein (cysteine-139) is presumed to have the same role. However, as we have previously suggested (5), the two cysteine residues could generate a di-sulphide bridge forming a loop of 38 amino acids through which DNA may pass.

In this paper, we describe the construction of genes which encode altered forms of the *ogt* protein in which the two cysteine residues in question have been substituted by glycines. The specific activities of these mutant enzymes in crude extracts have been measured in order to determine the importance of each cysteine in generating functionally active protein.

Materials and Methods

Recombinant DNA Techniques

All recombinant DNA manipulations employed standard procedures (9).

Site Directed Mutagenesis. The *ogt* gene sequence (5) was available as a 650 bp *Eco*R1 fragment which was ligated into M13 mp19 (Boehringer Mannheim) in order to generate single stranded DNA. Site directed mutagenesis was performed using the Bio-Rad Mutagenesis *in vitro* mutagenesis kit (10). Oligonucleotides were synthesized on a DuPont 3000 Coder using standard phosphoramidite chemistry and purified by urea polyacrylamide gel electrophoresis.

Preparation of Bacterial Cell Extracts. A 2 ml aliquot of the bacterial culture was harvested by centrifugation at 14,000 x g for one minute at 4 °C and the pellet resuspended in 50 mM Tris-HCl, pH 8.3, 1 mM EDTA, 3 mM dithiothreitol. Following disruption by sonication on ice for two periods of 10 seconds each at 12 μ m peak to peak distance, phenylmethylsulphonyl fluoride in ethanol was added to a final concentration of 0.5 mM and cellular debris was removed by centrifugation (10,000 x g for 10 minutes at 4 °C). Supernatants were used for protein estimation (Bio-Rad) and for ATase assay.

Alkyltransferase Assay. This assay has been previously described (4). Briefly, cell extracts were incubated with calf-thymus DNA that had been methylated *in vitro* by reaction with [³H]MNU. Following incubation with the substrate DNA for 2 hours at 37 °C, the DNA was hydrolysed in 1 M perchloric acid at 75 °C for 40 minutes and labelled proteins were recovered by centrifugation and quantitated by liquid scintillation counting. The amount of protein in the cell extracts was determined and the ATase specific activity was calculated as fmole/mg of total protein.

Production of anti-ogt Polyclonal Antibodies. The *ogt* gene was ligated into the bacterial expression vector pET-3a (11) under the control of a T7 RNA polymerase dependent promoter. Following transformation into *E. coli* BL21-pLys-E which expressed T7 RNA polymerase under the control of the *lacUV5* promoter (11), colonies were expanded and one was selected for highest level expression of *ogt* ATase. The *ogt* protein was purified from the bacteria as previously described (12) by chromatography on double stranded DNA cellulose and Sephacryl S-200 HR. Purified protein, 550 μ g, was emulsified with incomplete Freund's adjuvant (Sigma) and injected subcutaneously at two-weekly intervals into the dorsal flanks of two half-lop eared rabbits over a period of 2 months. Blood was taken from ear veins and following removal of coagulated red cells by centrifugation (3,000 x g, 15 minutes at 4 °C) the resulting serum was stored at -70 °C.

Western Analysis. Polyacrylamide gel electrophoresis was performed using the Bio-Rad Mini Protean II system and the resulting gels were electroblotted to Hybond-C nitrocellulose (Amersham) using Bio-Rad electroblotting apparatus. The filters were preabsorbed by incubation with an extract of *E. coli* JRG1728 (a gift from J.R. Guest) from which the *ogt* gene has been deleted and then incubated with a 1:1000 dilution of the anti-*ogt* polyclonal antibody. The second antibody used was swine-anti-rabbit IgG (Dako Ltd) which was followed by an incubation with a peroxidase anti-peroxidase complex raised in rabbits (Dako Ltd). The peroxidase substrate consisted of 0.5 mg/ml 3',3'-Diaminobenzidine -4 HCl, 0.03% hydrogen peroxide in a 50 mM tris, 10 mM imidazole buffer, pH 7.5.

Results

Site-directed mutagenesis was performed on two cysteine residues within the *ogt* protein. The oligonucleotides synthesized for the mutagenesis and the amino acid substitutions made are shown in Fig. 2. The oligonucleotides introduced novel restriction endonuclease recognition sites in order that the presence of the desired mutations could be confirmed. The *ogt* gene was mutated to encode three altered proteins: 1 with a glycine residue substituting cysteine-102, 2 with a glycine residue substituting cysteine-139 and 3 in which both cysteines were substituted for glycines. Glycine was chosen for the substitutions since it has similar physico-chemical properties to cysteine (13).




Figure 4

Histogram showing the ATase specific activities of JM101 extracts containing plasmids expressing the wild-type (WT) and mutant *ogt* proteins. Clone 1 - mutated cysteine 102, clone 2 - mutated cysteine 139, clone 3 - mutated cysteines 102 and 139.

residues, expressed very low levels of ATase; <150 fmole/mg prior to and following induction.

To investigate the possibility that the slightly reduced ATase specific activity of protein 1 was due to a slower rate of action of the mutant ATase enzyme on the substrate DNA, a fixed amount of either wild-type *ogt* ATase or protein 1 were incubated with excess [^3H]-MNU treated DNA for increasing lengths of time in a standard ATase assay. However, no difference in the reaction rates of the two enzymes was seen (Fig. 5), indicating that this was not the reason for the lower ATase activities.

The presence of the wild type and mutated *ogt* fusion proteins in extracts of JM101 *E. coli* was confirmed by Western analysis using *ogt* polyclonal antibodies (Fig. 6). The *ogt*




Figure 5

The rate of action of wild-type and protein 1 on [^3H]-MNU treated substrate DNA.




Figure 6

Western analysis of the wild-type and mutagenized *ogt* proteins probed with anti-*ogt* polyclonal antibodies. Lanes 1-6 are all extracts of JM101 which had been transformed with different constructs. 1 - Wild-type *ogt* in pUC8.1; 2 - Clone 1 (mutated Cysteine-102); 3 - Clone 2 (mutated cysteine 139); 4 - Clone 3 (mutated cysteines 102 and 139); 5 - pUC8.1; 6 - JM101 alone; 7 - Double stranded DNA cellulose purified *ogt* ATase; M - Protein molecular weight markers, not visible.

ATase encoded by the host *E. coli ogt* gene was represented by a 19 kDa protein band in every lane. A larger 21.5 kDa band corresponding to the plasmid-encoded fusion protein (Fig. 3) was also present in every lane containing extracts of JM101 harboring the pUC8.1-*ogt* constructs.

Discussion

The results of these site directed mutagenesis studies indicate that cysteine residue 139 is the alkyl-accepting cysteine residue in the *ogt* ATase. This is not surprising since the protein sequences of ten ATase enzymes are now known and nine contain the same pentameric region of homology (PCHRV), at the active-site (see reference 15 for a recent comparison of all the known ATase sequences except for the Chinese hamster (16)). The cysteine residue within this sequence has actually been confirmed as the alkyl-accepting cysteine residue for the *ada* (8,17), the human (18) and the mouse (19) ATase enzymes. Substitution of cysteine residue 102 had little effect, if any, on the activity of the repair protein demonstrating that if the two cysteine residues are involved in the formation of a disulphide bridge, as suggested in the introduction, its structure is not essential for the removal of O⁶-methylguanine from DNA. The heptameric (LRTIPCG) sequence, containing cysteine-102, is unique to the two *E. coli* enzymes and because these are the only two ATases known to efficiently repair O⁴-alkylthymine (12,20), it is possible that this region may be involved in the repair of this adduct.

Acknowledgments

This work was supported by the Cancer Research Campaign. We thank Dr. J.R. Guest for the gift of the *E. coli* JRG1728 and Dr. J. Brennand for the plasmid pUC8.1.

References

- 1) Saffhill, R., Margison, G.P., and O'Connor, P.J. (1985) *Biochim. Biophys. Acta* 823, 111-145.
- 2) Olsson, M., and Lindahl, T. (1980) *J. Biol. Chem.* 255, 10569-10571.
- 3) Sedgwick, B. (1983) *Mol. Gen. Genet.* 191, 466-472.
- 4) Margison, G.P., Cooper, D.P., and Brennand, J. (1985) *Nucleic Acids Res.* 13, 1939-1952.
- 5) Potter, P.M., Wilkinson, M.C., Fitton, J., Carr, F.J., Brennand, J., Cooper, D.P., and Margison, G.P. (1987) *Nucleic Acids Res.* 15, 9177-9193.
- 6) Potter, P.M., Kleibl, K., Cawkwell, L., and Margison, G.P. (1989) *Nucleic Acids Res.* 17, 8047-8060.
- 7) Schendel, P.F., and Robins, P.E. (1979) *Proc. Natl. Acad. Sci. USA* 75, 6017-6020.
- 8) Takano, K., Nakabeppu, Y., and Sekiguchi, M. (1988) *J. Mol. Biol.* 201, 261-271.
- 9) Maniatis, T., Fritsch, E.F., and Sambrook, J. (1982) In *Molecular Cloning: A Laboratory Manual*. Cold Spring Harbor Laboratory.
- 10) Kunkel, T., Roberts, J.D., and Zakour, R.A. (1987) *Methods in Enzymology* 154, 367-382.
- 11) Rosenberg, A., Lade, B., Chui, D., Lin, S., Dunn, J., and Studier, F. (1987) *Gene* 56, 125-135.
- 12) Wilkinson, M.D., Potter, P.M., Cawkwell, L., Georgiadis, P., Patel, D., Swann, P.F., and Margison, G.P. (1989) *Nucleic Acids Res.* 17, 8475-8484.
- 13) Taylor, W.R. (1986) *J. Theor. Biol.* 119, 205-218.
- 14) Hanna, Z., Fregean, C., Prefontaine, G., and Brousseau, R. (1984) *Gene* 30, 247-250.
- 15) Shiraishi, A., Sakumi, K., Nakatsu, Y., Hayakawa, H., and Sekiguchi, M. (1992) *Carcinogenesis* 13, 289-296.
- 16) Rafferty, J.A., Elder, R.H., Watson, A.J., Cawkwell, C., Potter, P.M., and Margison, G.P. (1992) *Nucleic Acids Res.* 20, 1891-1895.
- 17) Ling-Ling, C., Nakamura, T., Nakatsu, Y., Sakumi, K., Hayakawa, H., Sekiguchi, M. (1992) *Carcinogenesis* 13, 837-843.
- 18) von Wronski, M.A., Shiota, S., Tano, K., Mitra, S., Bigner, D.D., and Brent, T.P. (1991) *J. Biol. Chem.* 266, 1064-1070.
- 19) Shiota, S., von Wronski, M.A., Tano, K., Bigner, D.D., Brent, T.P., and Mitra, S. (1992) *Biochemistry* 31, 1897-1903.
- 20) Koike, G., Maki, H., Takeya, H., Hayakawa, H., and Sekiguchi, M. (1990) *J. Biol. Chem.* 265, 14754-14762.